Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2024

Fein JA, Patel SS. Under AI's lens: spotting mutations visually. Blood Adv. 2024;8(3):827-828.

Geyer JT. Current Challenges in the Characterization of Myeloid Neoplasms. Pathobiology. 2024;91(1):5-7.

Monge J, Razavi M, Bao L, Patel SS. Two p53s in a Pod: Co-occurring plasma cell myeloma and therapy-related myeloid neoplasm following lenalidomide therapy. Am J Hematol. 2024;99(2):327-328.

VandenBussche CJ, Nwosu A, Souers R, Sundling KE, Brainard J, Goyal A, et al. The Implementation of Nongynecologic Reporting Systems in Cytopathology Laboratories Is Highly Variable: Analysis of Data From a 2020 Supplemental Survey of Participants in the College of American Pathologists Interlaboratory Comparison Program in . Arch Pathol Lab Med. 2024;148(5):531-537.

Ntiri M, Nazarian A, Magro C, Alexis AF. Nodular (keloidal) scleroderma: A case series of 5 patients. JAAD Case Rep. 2024;49:135-139.

Goyal A, Booth CN, Souers RJ, Tabbara SO, Roberson J, Henry MR, et al. Navigating Practice Issues Related to the Unsatisfactory Cervicovaginal Papanicolaou Test: Survey Results of Laboratories Participating in the 2020 College of American Pathologists PAP Education Program. Arch Pathol Lab Med. 2024;148(1):48-54.

Furtado LV, Bifulco C, Dolderer D, Hsiao SJ, Kipp BR, Lindeman NI, et al. Recommendations for Tumor Mutational Burden Assay Validation and Reporting: A Joint Consensus Recommendation of the Association for Molecular Pathology, College of American Pathologists, and Society for Immunotherapy of Cancer. J Mol Diagn. 2024;26(8):653-668.

Sosa BR, Cung M, Suhardi VJ, Morse K, Thomson A, Yang HS, et al. Capacity for large language model chatbots to aid in orthopedic management, research, and patient queries. J Orthop Res. 2024.

Lin C, Greenblatt M, Gao G, Shim J-. Development of AAV-Mediated Gene Therapy Approaches to Treat Skeletal Diseases. Hum Gene Ther. 2024.

Tse P, Yan J, Liu Y, Jamula E, Heddle N, Bazin R, et al. Quality of life and cost-effectiveness of convalescent plasma compared to standard care for hospitalized COVID-19 patients in the CONCOR-1 trial. Transfusion. 2024.